About this webinar
Dyslipidaemia is one of the major risk factors for cardiovascular disease (CVD). In this interactive webinar, Prof Alberico L. Catapano, one of the co-chairs of the 2019 ESC/EAS Dyslipidaemia Guidelines, will discuss the rationale behind the revision of the Guidelines, covering the biological, epidemiological and clinical background that made it necessary to update them.
Emphasis will be placed on the new goals and the clinical evidence supporting them. The dual goals for high and very-high risk will also be discussed, together with the role of apolipoprotein B /non HDL goals in patients with metabolic syndrome and diabetes.
This webinar comprises a 15-min presentation, in which Prof Catapano will cover the new Guidelines in the prevention of CVD, followed by Q&A.
Take the opportunity to understand how the new Guidelines apply to your practice, and put your questions on this topic to Guidelines co-chair Prof Catapano in this interactive webinar.
This webinar is primarily suited to physicians in general practice.
It is highly relevant to nurses and healthcare practitioners working in lipid clinics, in cardiovascular prevention, in diabetes and in many other clinics training care of patients with cardiovascular or metabolic diseases.
Others who will find the educational content of this webinar to be relevant include scientists working in cardiovascular epidemiology and in basic cardiovascular research, physicians working in in internal medicine, cardiology, diabetology, endocrinology, and persons employed in the pharma industry.
ABOUT THE PRESENTER
Alberico L. Catapano is Full Professor of Pharmacology at the University of Milano, Director of the Laboratory for the study of Lipoproteins and Atherosclerosis and of the Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis (S.I.S.A.) at the “Bassini” Hospital. He is also the Director of Center of Epidemiology and Preventive Pharmacology of the University of Milano (SEFAP).
Professor Catapano is Past President of the European Atherosclerosis Society (EAS), and the Chairman of the EAS/ESC Guidelines for the treatment of dyslipoproteinemias. He holds board positions in several learned Scientific Societies including the Italian Society for the Study of Atherosclerosis ; he is also President of the Italian Society of Clinical and Experimental Therapy (SITeCS) and General Director of the SISA Foundation.
He has authored more than 400 scientific papers in peer reviewed journals and of several books in the area of the Atherosclerosis, Lipoproteins and Lipid Metabolism. He is the editor of Atherosclerosis Supplements and also co editor of “Atherosclerosis” and associate editor of other scientific journals.
EAS has independently organised all matters related to these webinars, including content and presenters. We acknowledge financial support, in the form of an unrestricted educational grant, received from Sanofi and Regeneron in support of the programme.
Director Center of Epidemiology and Preventive Pharmacology Director Laboratory of Lipoproteins, Immunity and Atherosclerosis Department of Pharmacological and Biomolecular Sciences Director Center for the Study of Atherosclerosis
The European Atherosclerosis Society (EAS) was founded in 1964 with the aim of “advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease”. For more than 50 years the Society’s exp...
Share this webinar